Clinical trialUNITERAREMay 4
New Recruiting Trial: A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
Researchers are testing a new tool called HB-2121 to help diagnose celiac disease, a condition where eating gluten damages the small intestine. This is the first study in patients to make sure the tool is safe and works well. The study is now accepting volunteers and will start in May 2026.
WHY IT MATTERSThis trial offers celiac disease patients a potential new diagnostic approach that could improve how doctors identify the condition, though it's still in early safety testing phases.